PMID- 36567210
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230214
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 23
IP  - 2
DP  - 2023 Feb
TI  - Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed 
      Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational 
      Study Using Czech Registry Data.
PG  - 145-153
LID - S2152-2650(22)01718-9 [pii]
LID - 10.1016/j.clml.2022.11.001 [doi]
AB  - BACKGROUND: Although novel therapies improved prognosis of multiple myeloma (MM) 
      patients, clinical outcomes in the multi-refractory population are still poor. 
      PATIENTS AND METHODS: We reviewed data from the Czech Registry of Monoclonal 
      Gammopathies, identified and characterized triple-class exposed (3CE) 
      relapsed/refractory MM patients, treatment patterns after 3CE, assessed overall 
      survival (OS), progression-free survival (PFS), time to next treatment (TTNT), 
      explored cohorts with and without triple- and penta-refractoriness. RESULTS: In 
      83 3CE patients who started subsequent therapies, the median OS was 14.2 months 
      (95% CI, 8.5-19.9), PFS 6.2 months (95% CI, 3.9-8.5), and TTNT 7.2 months (95% 
      CI, 4.6-9.8). Triple- and penta-class refractory patients had a significantly 
      worse prognosis in all outcomes. Their life expectancy was shorter, the disease 
      progression started earlier, and the TTNT was shorter, which increased likelihood 
      of becoming refractory to more therapies. Time-to-event results from the first 
      index date and all index dates analyses were very similar. CONCLUSION: Similar to 
      previous studies from the US and Europe, our results show a high disease burden. 
      Introduction of novel therapies, such as CAR-T cells, new bispecific and 
      trispecific monoclonal antibodies, and other drugs, is expected to bring 
      significant benefits to these patients.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Maisnar, Vladimir
AU  - Maisnar V
AD  - Fourth Department of Internal Medicine - Hematology, University Hospital and 
      Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech 
      Republic.
FAU - Pour, Ludek
AU  - Pour L
AD  - Department of Internal Medicine, Hematology and Oncology, University Hospital 
      Brno, Brno, Czech Republic.
FAU - Spicka, Ivan
AU  - Spicka I
AD  - Department of Hematology, First Faculty of Medicine, General University Hospital 
      in Prague, Prague, Czech Republic.
FAU - Jelinek, Tomas
AU  - Jelinek T
AD  - Department of Hemato-Oncology, University Hospital Ostrava and Faculty of 
      Medicine, University of Ostrava, Ostrava, Czech Republic.
FAU - Minarik, Jiri
AU  - Minarik J
AD  - Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech 
      Republic.
FAU - Jungova, Alexandra
AU  - Jungova A
AD  - Department of Hemato-Oncology, University Hospital Pilsen, Pilsen, Czech 
      Republic.
FAU - Stork, Martin
AU  - Stork M
AD  - Department of Internal Medicine, Hematology and Oncology, University Hospital 
      Brno, Brno, Czech Republic.
FAU - Straub, Jan
AU  - Straub J
AD  - Department of Hematology, First Faculty of Medicine, General University Hospital 
      in Prague, Prague, Czech Republic.
FAU - Radocha, Jakub
AU  - Radocha J
AD  - Fourth Department of Internal Medicine - Hematology, University Hospital and 
      Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech 
      Republic.
FAU - Pika, Tomas
AU  - Pika T
AD  - Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky 
      University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
FAU - Pospisilova, Lenka
AU  - Pospisilova L
AD  - Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic.
FAU - Nair, Sandhya
AU  - Nair S
AD  - Janssen Global Services, Beerse, Belgium.
FAU - Kunovszki, Peter
AU  - Kunovszki P
AD  - Janssen Global Services, Budapest, Hungary.
FAU - Hajek, Roman
AU  - Hajek R
AD  - Department of Hemato-Oncology, University Hospital Ostrava and Faculty of 
      Medicine, University of Ostrava, Ostrava, Czech Republic. Electronic address: 
      roman.hajek@fno.cz.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20221106
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
SB  - IM
MH  - Humans
MH  - Czech Republic/epidemiology
MH  - *Multiple Myeloma/drug therapy
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Registries
OTO - NOTNLM
OT  - CAR-T eligible patients
OT  - Heavily pretreated patients
OT  - Late-line disease
OT  - Real-world evidence
OT  - Survival analysis
EDAT- 2022/12/26 06:00
MHDA- 2023/01/31 06:00
CRDT- 2022/12/25 21:56
PHST- 2022/09/19 00:00 [received]
PHST- 2022/10/31 00:00 [revised]
PHST- 2022/11/03 00:00 [accepted]
PHST- 2022/12/26 06:00 [pubmed]
PHST- 2023/01/31 06:00 [medline]
PHST- 2022/12/25 21:56 [entrez]
AID - S2152-2650(22)01718-9 [pii]
AID - 10.1016/j.clml.2022.11.001 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):145-153. doi: 
      10.1016/j.clml.2022.11.001. Epub 2022 Nov 6.